Xenova launches £11m rights issue
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The biotechnology company Xenova yesterday unveiled plans to raise £11m in a move that will give it an 18-month window to carry on developing its cancer drugs.
It is raising the cash, equating to £9.9m of funds net of expenses, through a rights issues of 33.7 million shares priced at 32.5p each – a 25 per cent discount to Tuesday's closing price.
Shares in Xenova closed down 12 per cent, or 5.25p, at 38p yesterday. The eight-for-33 rights issue has been fully underwritten by Nomura.
David Oxlade, the chief executive, said the money would help the company continue to develop and further strengthen its portfolio of drugs and "progress a number of new drug candidates towards or into clinical trials".
In particular, the company plans to progress its key drug, tariquidar, through phase III clinical trials as well as progress various addiction vaccines through clinical trials. Xenova has eight products in clinical trials and a further eight in pre-clinical development.
"The directors believe that the additional financial strength resulting from the rights issue will put the group in a better position to negotiate favourable terms for its licensing agreements or any other corporate transactions," it said.
Nevertheless, Xenova said that losses and cash outflows would continue for "a number of years" and said the timing of further fundraisings would depend on the "timing and magnitude" of sales. At the end of June, the company had £15.1m of cash.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments